Alluvi, previously BI 4744, represents a notable development in obesity care. This dual stimulator targeting both GLP-1 and GIP sites demonstrates remarkable results in patient studies, potentially surpassing available https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/